504 367

Cited 232 times in

Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy

DC Field Value Language
dc.contributor.author정준-
dc.contributor.author박병우-
dc.date.accessioned2018-07-20T07:37:25Z-
dc.date.available2018-07-20T07:37:25Z-
dc.date.issued2017-
dc.identifier.issn0028-4793-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/160344-
dc.description.abstractBACKGROUND: Patients who have residual invasive carcinoma after the receipt of neoadjuvant chemotherapy for human epidermal growth factor receptor 2 (HER2)-negative breast cancer have poor prognoses. The benefit of adjuvant chemotherapy in these patients remains unclear. METHODS: We randomly assigned 910 patients with HER2-negative residual invasive breast cancer after neoadjuvant chemotherapy (containing anthracycline, taxane, or both) to receive standard postsurgical treatment either with capecitabine or without (control). The primary end point was disease-free survival. Secondary end points included overall survival. RESULTS: The result of the prespecified interim analysis met the primary end point, so this trial was terminated early. The final analysis showed that disease-free survival was longer in the capecitabine group than in the control group (74.1% vs. 67.6% of the patients were alive and free from recurrence or second cancer at 5 years; hazard ratio for recurrence, second cancer, or death, 0.70; 95% confidence interval [CI], 0.53 to 0.92; P=0.01). Overall survival was longer in the capecitabine group than in the control group (89.2% vs. 83.6% of the patients were alive at 5 years; hazard ratio for death, 0.59; 95% CI, 0.39 to 0.90; P=0.01). Among patients with triple-negative disease, the rate of disease-free survival was 69.8% in the capecitabine group versus 56.1% in the control group (hazard ratio for recurrence, second cancer, or death, 0.58; 95% CI, 0.39 to 0.87), and the overall survival rate was 78.8% versus 70.3% (hazard ratio for death, 0.52; 95% CI, 0.30 to 0.90). The hand-foot syndrome, the most common adverse reaction to capecitabine, occurred in 73.4% of the patients in the capecitabine group. CONCLUSIONS: After standard neoadjuvant chemotherapy containing anthracycline, taxane, or both, the addition of adjuvant capecitabine therapy was safe and effective in prolonging disease-free survival and overall survival among patients with HER2-negative breast cancer who had residual invasive disease on pathological testing. (Funded by the Advanced Clinical Research Organization and the Japan Breast Cancer Research Group; CREATE-X UMIN Clinical Trials Registry number, UMIN000000843 .).-
dc.description.statementOfResponsibilityopen-
dc.formatapplication/pdf-
dc.languageEnglish-
dc.publisherMassachusetts Medical Society-
dc.relation.isPartOfNEW ENGLAND JOURNAL OF MEDICINE-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.rightshttps://creativecommons.org/licenses/by-nc-nd/2.0/kr/-
dc.subject.MESHAdult-
dc.subject.MESHAged-
dc.subject.MESHAntimetabolites, Antineoplastic/adverse effects-
dc.subject.MESHAntimetabolites, Antineoplastic/therapeutic use-
dc.subject.MESHBreast Neoplasms/drug therapy-
dc.subject.MESHBreast Neoplasms/mortality-
dc.subject.MESHBreast Neoplasms/surgery-
dc.subject.MESHCapecitabine/adverse effects-
dc.subject.MESHCapecitabine/therapeutic use-
dc.subject.MESHChemotherapy, Adjuvant/adverse effects-
dc.subject.MESHFemale-
dc.subject.MESHHand-Foot Syndrome/etiology-
dc.subject.MESHHumans-
dc.subject.MESHMiddle Aged-
dc.subject.MESHNeoadjuvant Therapy-
dc.subject.MESHNeoplasm Staging-
dc.subject.MESHPreoperative Care-
dc.subject.MESHReceptor, ErbB-2-
dc.subject.MESHSurvival Analysis-
dc.subject.MESHTriple Negative Breast Neoplasms/drug therapy-
dc.subject.MESHTriple Negative Breast Neoplasms/mortality-
dc.titleAdjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine-
dc.contributor.departmentDept. of Surgery-
dc.contributor.googleauthorNorikazu Masuda-
dc.contributor.googleauthorSoo-Jung Lee-
dc.contributor.googleauthorShoichiro Ohtani-
dc.contributor.googleauthorYoung-Hyuck Im-
dc.contributor.googleauthorEun-Sook Lee-
dc.contributor.googleauthorIsao Yokota-
dc.contributor.googleauthorKatsumasa Kuroi-
dc.contributor.googleauthorSeock-Ah Im-
dc.contributor.googleauthorByeong-Woo Park-
dc.contributor.googleauthorSung-Bae Kim-
dc.contributor.googleauthorYasuhiro Yanagita-
dc.contributor.googleauthorShinji Ohno-
dc.contributor.googleauthorShintaro Takao-
dc.contributor.googleauthorKenjiro Aogi-
dc.contributor.googleauthorHiroji Iwata-
dc.contributor.googleauthorJoon Jeong-
dc.contributor.googleauthorAeree Kim-
dc.contributor.googleauthorKyong-Hwa Park-
dc.contributor.googleauthorHironobu Sasano-
dc.contributor.googleauthorYasuo Ohashi-
dc.contributor.googleauthorMasakazu Toi-
dc.identifier.doi10.1056/NEJMoa1612645-
dc.contributor.localIdA03727-
dc.relation.journalcodeJ02371-
dc.identifier.eissn1533-4406-
dc.identifier.pmid28564564-
dc.contributor.alternativeNameJeong, Joon-
dc.contributor.affiliatedAuthorJeong, Joon-
dc.citation.volume376-
dc.citation.number22-
dc.citation.startPage2147-
dc.citation.endPage2159-
dc.identifier.bibliographicCitationNEW ENGLAND JOURNAL OF MEDICINE, Vol.376(22) : 2147-2159, 2017-
dc.identifier.rimsid41520-
dc.type.rimsART-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Surgery (외과학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.